Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication.
Nganou-Makamdop K, Billingsley JM, Yaffe Z, O'Connor G, Tharp GK, Ransier A, Laboune F, Matus-Nicodemos R, Lerner A, Gharu L, Robertson JM, Ford ML, Schlapschy M, Kuhn N, Lensch A, Lifson J, Nason M, Skerra A, Schreiber G, Bosinger SE, Douek DC.
Nganou-Makamdop K, et al. Among authors: kuhn n.
PLoS Pathog. 2018 Aug 24;14(8):e1007246. doi: 10.1371/journal.ppat.1007246. eCollection 2018 Aug.
PLoS Pathog. 2018.
PMID: 30142226
Free PMC article.